| Montrouge, France, June 22, 2018 |
DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel
Shareholders approve all proposed resolutions
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting, which was chaired by Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies. At the General Meeting, the Company's shareholders approved all resolutions submitted by the Board of Directors. These resolutions are posted on the Investors & Media section of the Company's website, https://www.dbv-technologies.com/investor-relations/ .
The Company also announced that Joan Schmidt has been appointed as Executive Vice President, General Counsel. She will be responsible for all legal affairs and compliance at DBV, reporting to the Deputy Chief Executive Officer, David Schilansky. Joan will also serve as a member of the Executive Committee.
" We are thrilled to welcome Joan as we continue to expand the breadth of talent of our leadership team, " said David Schilansky , Deputy CEO of DBV Technologies. "Joan has shown a consistent track record of success, and her legal, business and industry background will be an asset as we advance potential new treatments for food allergies."
Joan Schmidt joins DBV after three years at Biotronik, a global medical device company, where she was Executive Vice President, Legal & Human Resources, General Counsel and Secretary. Previously, she held various positions of increasing responsibility at Novo Nordisk, most recently as Corporate Vice President, Legal Affairs. Earlier in her career, she was an associate in the litigation group of a private law firm in New York, NY. Joan earned a J.D. from Pace University and a B.A. from the University of Connecticut.
Joan Schmidt said, "DBV's mission to develop potentially transformative treatments for patients with food allergies and other immunological diseases, with its novel Viaskin technology platform, is something I am passionate about. I look forward to building out a team that can support the potential launch of DBV's first potential product for the treatment of peanut allergy, if Viaskin Peanut is approved."
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company's ordinary shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
DBV Investor Relations Contact Sara Blum Sherman Senior Director, Investor Relations & Strategy +1 212-271-0740 sara.sherman@dbv-technologies.com
DBV Media Contact Raul Damas Partner, Brunswick Group +1-212-333-3810 DBV@brunswickgroup.com
Attachment
